Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 22260002 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#22260002, RRID:AB_10004656
- Product name
- Rabbit Polyclonal Lysine (K)-specific Demethylase 5B/KDM5B/JARID1B Antibody
- Antibody type
- Polyclonal
- Antigen
- This antibody is specific for the Middle Region of the target protein (NM_006618).
- Reactivity
- Human
- Host
- Rabbit
- Vial size
- 0.05 mg
- Storage
- Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Submitted references KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance.
Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma.
Proteomic Analysis, Immune Dysregulation, and Pathway Interconnections with Obesity.
Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.
High-throughput screening for native autoantigen-autoantibody complexes using antibody microarrays.
The significance of a Cripto-1 positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics.
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.
Hinohara K, Wu HJ, Vigneau S, McDonald TO, Igarashi KJ, Yamamoto KN, Madsen T, Fassl A, Egri SB, Papanastasiou M, Ding L, Peluffo G, Cohen O, Kales SC, Lal-Nag M, Rai G, Maloney DJ, Jadhav A, Simeonov A, Wagle N, Brown M, Meissner A, Sicinski P, Jaffe JD, Jeselsohn R, Gimelbrant AA, Michor F, Polyak K
Cancer cell 2018 Dec 10;34(6):939-953.e9
Cancer cell 2018 Dec 10;34(6):939-953.e9
Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma.
Noguchi F, Inui S, Fedele C, Shackleton M, Itami S
Molecular cancer therapeutics 2017 May;16(5):936-947
Molecular cancer therapeutics 2017 May;16(5):936-947
Proteomic Analysis, Immune Dysregulation, and Pathway Interconnections with Obesity.
Garrison CB, Lastwika KJ, Zhang Y, Li CI, Lampe PD
Journal of proteome research 2017 Jan 6;16(1):274-287
Journal of proteome research 2017 Jan 6;16(1):274-287
Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.
Yuan P, Ito K, Perez-Lorenzo R, Del Guzzo C, Lee JH, Shen CH, Bosenberg MW, McMahon M, Cantley LC, Zheng B
Proceedings of the National Academy of Sciences of the United States of America 2013 Nov 5;110(45):18226-31
Proceedings of the National Academy of Sciences of the United States of America 2013 Nov 5;110(45):18226-31
High-throughput screening for native autoantigen-autoantibody complexes using antibody microarrays.
Rho JH, Lampe PD
Journal of proteome research 2013 May 3;12(5):2311-20
Journal of proteome research 2013 May 3;12(5):2311-20
The significance of a Cripto-1 positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics.
Strizzi L, Margaryan NV, Gilgur A, Hardy KM, Normanno N, Salomon DS, Hendrix MJ
Cell cycle (Georgetown, Tex.) 2013 May 1;12(9):1450-6
Cell cycle (Georgetown, Tex.) 2013 May 1;12(9):1450-6
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.
Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, Körbel C, Laschke MW, Gimotty PA, Philipp SE, Krause E, Pätzold S, Villanueva J, Krepler C, Fukunaga-Kalabis M, Hoth M, Bastian BC, Vogt T, Herlyn M
Cancer cell 2013 Jun 10;23(6):811-25
Cancer cell 2013 Jun 10;23(6):811-25
No comments: Submit comment
No validations: Submit validation data